Skip to main
VSTM
VSTM logo

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 59%
Buy 35%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Verastem Inc. is showing a positive trajectory, driven by recent advancements and upcoming catalysts, particularly in their lead program's focus on the LGSOC KRAS-mt population. The company has exercised its option to license VS-7375 from GenFleet, reflecting confidence in its potential to outperform competitors in the G12D inhibitor space, with estimates suggesting peak sales could reach $250M–$300M. Additionally, the favorable safety profile of VS-7375, indicated by the absence of dose-limiting toxicities and promising preclinical efficacy data, further enhances investor optimism regarding its market potential and valuation prospects.

Bears say

Verastem Inc. has experienced volatility in its stock price, rebounding to the mid-single digits following a priority review by the FDA. However, concerns arise regarding potential dilution effects if the company raises capital at lower valuations than current estimates, which could negatively impact shareholder value. Additionally, the risk of insufficient efficacy or safety of its lead asset in clinical trials poses a significant threat to further development and could lead to substantial downward pressure on the stock price.

Verastem (VSTM) has been analyzed by 17 analysts, with a consensus rating of Buy. 59% of analysts recommend a Strong Buy, 35% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Buy based on their latest research and market trends.

According to 17 analysts, Verastem (VSTM) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.